James Wm. Forsythe, MD, HMD  
Board Certified Medical Oncologist  
Board Certified Internal Medicine  
Certified in Homeopathy

www.DrForsythe.com  
info@DrForsythe.com  
www.CenturyWellness.com  
RenoWellnessDr@yahoo.com

The Immune Protocol™  
The Lite LDIPT Protocol™  
Out-Come Based Investigation  
750 Patients - 54 Months  
From 06/10 - 12/14  
Using CST
This presentation has been peer-reviewed for fair and balanced evidence-based medicine.

Status of FDA devices used for the material being presented:
NA/Non-Clinical

Status of off-label use of devices, drugs or other materials that constitute the subject of this presentation: Discuss off-label use of chemotherapy drugs for different cancers.
Integrative Medical Oncology Philosophy

“In Stage IV adult cancers of any origin improvement in quality of life issues is directly proportional to improvement to overall response rate. Even stable disease can be tolerated and metamorphosed into a chronic livable condition.”

~James W Forsythe, MD, HMD~
Alternative Cancer Treatments
The Immune Protocol™ + The Lite LDIPT Protocol™

• Top Ten Take Home Points:
1. Integrative cancer medicine combines conventional and alternative treatments
2. Hope in victory over cancer with integrative cancer therapies
3. Genomic Testing (CST) on whole blood isolates circulating tumor blood cells
4. Genomic testing offers a blue print for individual’s cancer treatments
5. Genomic testing defines top chemo agents most effective in the treatment of one’s cancer
6. Genomic testing isolates supplements, herbs and vitamins that are most effective in the treatment of one’s cancer
7. Insulin Potentiated Therapy (IPT) uses insulin as its target agent
8. CST + IPT + Lipoic –Acid-Palladium (LAPd) Compound produces higher survivorship rates
9. Immune Protocol™ + Lite LDIPT Protocol™ + Lipoic –Acid-Palladium (LAPd) shows overall survivorship rate of 64% over a 54 month period in 750 Stage IV cancer patients
10. Freedom to choose alternative cancer treatments is your right
Original Mission Of
The Immune Protocol™ / The Lite LDIPT Protocol™

Test efficacy of CST + Lite LDIPT with the following:

1. Low-Dose Chemo + Immune Protocol™

2. Lipoic-Acid-Palladium (LAPd) Complex, IV

3. Immune Protocol™ + Lite LDIPT Protocol™ + CST

4. Lite LDIPT Protocol™
Three Goals of Study

1. To prove Integrative Cancer Treatments *NOT* only work but are *SUPERIOR* to current 5 year survival statistics as reported in the Clinical Journal of Oncology as 2.1% in adult Stage IV cancers after 5 years of chemotherapy.
Three Goals of Study (continued)

2. To prove using genetic chemo-sensitivity testing on circulating tumor blood cells (CTCs) provides a “Blueprint” for patients by pinpointing the most effective chemotherapy drugs, targeted agents, hormonal therapies and natural supplements in order to produce lasting durable remissions and possible “cures”.
Three Goals of Study (continued)

3. To prove that giving low-dose, non-toxic Insulin Potentiation Therapy (IPT) without employing the “therapeutic moment” can be equally effective without the risks of severe hypoglycemic reactions. This is called The Lite LDIPT Protocol™.
Inquiring Cancer Patients Want to Know

Question: What are your outcome survival statistics?

Answer: Results of CWC’s current outcome based study of 750 patients at 54 months.
Inquiring Cancer Patients
Want to Know

Questions:
What parameters are you measuring?

Answer:
The following parameters are recorded:
Inquiring Cancer Patients Want to Know (continued)

Answer:
The following parameters are recorded:

A. Initials of patient (HIPPA rules)
B. Date of Pathologic DX
C. Start date of The Forsythe Immune Protocol ™
D. Cancer DX
E. Prior Therapy
Inquiring Cancer Patients Want to Know (continued)

Answer:
The following parameters are recorded:

F. Use of LAPd
G. Whether given full-dose chemo or IPT Lite
H. Use of CST
I. Adverse events from therapy
J. Current status: CR, PR, SD, EX
The Immune Protocol ™/ Lite LDIPT Protocol ™
54 Month Report on 750 Stage IV
Adult Cancer Patients

Survival Column requirements:
1. Stable Remission for at least one month
2. Must have measurable parameters
Earlier
Lipoic-Acid-palladium- (LAp) Study
2004-2006

• 225 patients with Stage IV cancers of multiple origins
• Lipoic-Acid-palladium (LAPd)-alone
• LAPd + Chemotherapy
• Study audited by FDA

6 year Overall Survival (OS) rate of 32%
Lipoic-Acid Palladium- (LAPd)

THE PRODUCT

1. A patented palladium lipoic compound (LAPd)

2. MVA: Minerals: molybdenum, rhodium & ruthenium
   Vitamins: B1, B2, B12
   Amino Acids: formyl-mcthionine, acetylcysteine

3. Palladium (Pd) is a rare metal often combined with platinum in jewelry. M.W. 106 found in nature alloyed with platinum, copper and nickel. Highly conductive metal.

4. ALA a super antioxidant and detoxifier. It is both water and fat soluble. It is an effective chelator with heavy metals.

5. Ongoing study of 225 patients with Stage IV cancers of multiple origins at six years shows an Overall Survival (OS) of 32% when used alone or with chemotherapy.
## Past and Ongoing Clinical Outcome – Based Cancer Studies

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRODUCT</th>
<th>Mode of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002-2003</td>
<td>Paw-paw NSP</td>
<td>Energetics</td>
</tr>
<tr>
<td>2004-2006</td>
<td>Lipoic-Acid-Palladium (LAPd)</td>
<td>Hyper-energizes Promotes Apoptosis</td>
</tr>
<tr>
<td>2010- Present</td>
<td>Immune Protocol™ + CST + Lite LDIPT Protocol™</td>
<td>Immune Boosters + CST + Lite LDIPT</td>
</tr>
</tbody>
</table>
FINDING
THE “TRIGGER” FOR CANCER

<table>
<thead>
<tr>
<th>Potential Cause(s)</th>
<th>Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heavy Metal Toxins</td>
<td>Hair, Blood, Urine</td>
</tr>
<tr>
<td>Chemical Toxins</td>
<td>Blood ELISA</td>
</tr>
<tr>
<td>Allergies: food and</td>
<td></td>
</tr>
<tr>
<td>inhalants</td>
<td>Blood &amp; Skin</td>
</tr>
<tr>
<td>Viral and Fungal</td>
<td>HPV, HIV, EBV, HEP B/C</td>
</tr>
<tr>
<td>Etiologies</td>
<td></td>
</tr>
<tr>
<td>Immune Competence</td>
<td>Lymph Subset &amp; NKC panels</td>
</tr>
<tr>
<td>Hormonal Imbalance</td>
<td>Saliva &amp; Blood</td>
</tr>
</tbody>
</table>
Unique Characteristics of Cancer Cells Used in Integrative Oncology

- Simple Sugars – malignant cells have increased numbers of insulin receptors to attract sugar molecules (i.e. PET Scan basis)
- Acidity – A lower intracellular pH in the biological terrain is ideal for malignant cell growth – hence use the value of alkalinization – (i.e. zeolite, cesium or green powders)
- Hypoxia – Malignant cells use anaerobic metabolism primarily thus the value of various O2 therapies – HBO / H2O2 / Ozone
- Low Voltage – Malignant cells are low energy systems and produce only 5% ATP of normal cells – thus hyper-energizing therapy – LAPd
## Conventional Oncology
### Examples of First, Second & Third Line Chemo Protocols used in Stage IV Cancers

<table>
<thead>
<tr>
<th>Cancer Origin</th>
<th>Stage</th>
<th>1st</th>
<th>2nd</th>
<th>3rd</th>
</tr>
</thead>
<tbody>
<tr>
<td>BREAST</td>
<td>IV</td>
<td>Taxane Cytoxin/ADR</td>
<td>Xeloda</td>
<td>Navelbine</td>
</tr>
<tr>
<td>CRC</td>
<td>IV</td>
<td>FOLFOX +/- Avastin</td>
<td>FOLFERRI +/- Avastin</td>
<td>XELODA +/- Erbitux</td>
</tr>
<tr>
<td>H/N</td>
<td>IV</td>
<td>5FU/Carbo</td>
<td>Taxane</td>
<td>Erbitux +/- MTX</td>
</tr>
<tr>
<td>LUNG</td>
<td>IV</td>
<td>Carbo/Taxol</td>
<td>Tarceva</td>
<td>Nav/GEM</td>
</tr>
<tr>
<td>OVARY</td>
<td>IV</td>
<td>Carbo/Taxol</td>
<td>DOXIL</td>
<td>GEM/TOPO</td>
</tr>
<tr>
<td>PROSTATE</td>
<td>IV</td>
<td>Zoladex +/- Casodex</td>
<td>KETO/HC ZYTIGA</td>
<td>Taxotere/MITOX +/- Pred</td>
</tr>
</tbody>
</table>
1. HX & Physical Exam – tumors in skin, liver, spleen lymph nodes, etc…
2. X-Rays: tumors detectable in CXR, bone X-Rays, mammograms, etc…
3. CT Scanning: tumors detectable in brain, chest, abdomen, pelvis or bones*
4. Ultrasounds: breasts, GB., liver, ovaries, spleen, etc…
5. MRI’s: brain, neck, sinuses, joints, breasts, muscles, soft tissues, etc…
6. Pet Scans: total body scanning
7. Chemo-sensitivity Testing on whole blood
8. Hormonal balancing testing-saliva or blood
9. Appropriate tumor markers

*I discourage excessive use of CT/PET /BONE scanning
Excessive Imaging Used in Conventional Oncology

“Overuse of Imaging Adds $500 million in healthcare costs, 500 more cancer cases a year, study finds.”

* Source: The American Journal of Managed Care 11/14, Vol 20
Tumor Markers

1. Bladder - NMP-22, BTA
2. Breast - CEA, CA 27-29, CA-15-3
3. Colorectal – CEA, CA 19-9, 5HIAA (Carcinoids)
4. Esophagus – CEA, CA 19-9
5. Gastric – CEA, CA 19-9
6. Liver – AFP, CEA, & CA19-9
7. Lung – CEA, CA 19-9
8. Lymphomas - ESR, LDH, Beta – 2 Microglobulin, SPE
9. Myeloma - B2MG, SPE, LDH, ESR
10. Pancreas – CEA, CA 19-9
11. Prostate – PSA, Free PSA
12. Ovary – CA-125
13. Testes – AFP, HCG
## HISTORICAL CONTROLS
CHEMO-RESISTANT Stage IV
LITERATURE REVIEW - LONGEVITY

<table>
<thead>
<tr>
<th>CANCER ORIGIN</th>
<th>STAGE IV HISTORICAL CONTROLS (Chemo-resistant) on Longevity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>6 – 18 months</td>
</tr>
<tr>
<td>Colorectal</td>
<td>3 – 6 months</td>
</tr>
<tr>
<td>Head / Neck</td>
<td>4 – 8 months</td>
</tr>
<tr>
<td>Hematological</td>
<td>3 – 12 months</td>
</tr>
<tr>
<td>Lung</td>
<td>3 – 6 months</td>
</tr>
<tr>
<td>Prostate</td>
<td>6 – 12 months</td>
</tr>
</tbody>
</table>
THE IMMUNE PROTOCOL™
Proprietary Blend

1. Normal Saline
2. B Complex
3. Pyridoxine
4. Vitamin B-12
5. Vitamin C
6. Magnesium Chloride
7. L-Lysine
8. Zinc
9. DMSO
10. Folic Acid
11. L-Glutathione

24
### THE IMMUNE PROTOCOL™
### THE LITE LDIPT PROTOCOL™
### 750 Patient Safety Profile
### IV / Oral PLA / CST / Investigation

<table>
<thead>
<tr>
<th>Condition</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea / Vomiting</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Diarrhea (oral only)</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Short of Breath</td>
<td>&lt;5% (40 ml only)</td>
</tr>
<tr>
<td>Skin Rash</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>ABN Liver Tests</td>
<td>&lt;2%</td>
</tr>
<tr>
<td>Transfusion Reactions (shakes/chills)</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>ABN Renal Tests</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Sulfa Allergies (DMSO)</td>
<td>&lt;5%</td>
</tr>
</tbody>
</table>
New Technology – Genomic CST
Chemo-Sensitivity Testing

• Performed on whole blood
• High Tech Labs World-Wide (Korea, Germany, Greece)
• Cancer cells harvested from blood - grown in vitro
• Subjected to genetic decoding
• Results include: > 50 varieties of chemo drugs, targeted agents and > 50 individual supplements
• Protocol written marrying best drugs with effective supplements and hormonal blockers
• Produces blueprint for patient’s specific cancer
• The Lite Low-dose fractionated IPT ™ treatment offered
• Full dose chemotherapy offered
RGCC Graphic Results
RGCC Graphic Results

Supplement Grafting Class II

1. AHCC-Active HEXOSE Correlated Compound
2. NEW PME
3. PME
4. Mistletoe
5. Proteo-Xyme
6. Epimune Complex
7. Cats Claw Forte
8. Retensyme Forte

0 10 20 30 40 50
RGCC Graphic Results

Supplement Grafting Class III

1. Melatonin
2. Naltrexone
3. Resveratrol
4. Indol 3 Carbinol
5. Paw-Paw
6. Quercetin
7. Salvestrol
8. Curcumin
9. Arabinogalactan
10. Aromatase-PN
11. Dextrol
Benefits of CST Testing
Blueprint for patient’s chemotherapy treatment

• Identify the best hormonal and supplement therapies

• Identify the best separate tumor markers

• Identify the viral etiologies - HPV, HIV, EBV
  HEP B/C Test only

• Quantitate CTC number (RGCC only)

• SOT vaccine (RGCC only)
Century Wellness Clinic
521 Hamill Lane  •  Reno, Nevada  89511
(775) 827-0707 Voice  •  (775) 827-1006 Fax
info@dforsythe.com  •  http://www.dforsythe.com

Patient: __________  D.O.B.: __________  Dx.: __________  Date: __________
Ht: __________  Wt: __________  BSA: __________

**IPT ORDERS**

Premeds: Others:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anzemet</td>
<td>100mg</td>
</tr>
<tr>
<td>Benadryl</td>
<td>25mg</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>4mg</td>
</tr>
</tbody>
</table>

IPT Orders for: #1: __________  dose: __________
A. Drug #1 __________  Dilute in 250ml NS and deliver over 30min with 5 Units Regular Insulin.
B. Drug #2 __________  Dilute in 250 ml of NS – Run 30min.
C. Check FSBs every 20 min during A&B infusions. If BS is <40, give 50ml 50% Dextrose IVP, if>40, give same as at conclusion.
D. Repeat above: BIV Weekly __________  x ¾ weeks/1st mo. Then give one weekly ¾ weeks/mo x 3 months.

Supplements

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Labs

<table>
<thead>
<tr>
<th>Test</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC</td>
<td>weekly</td>
</tr>
<tr>
<td>CMP</td>
<td>monthly</td>
</tr>
<tr>
<td>CEA</td>
<td>/mo</td>
</tr>
<tr>
<td>CA 27-29</td>
<td>/mo</td>
</tr>
<tr>
<td>CA 19-9</td>
<td>/mo</td>
</tr>
<tr>
<td>AFP</td>
<td>/mo</td>
</tr>
<tr>
<td>CA 125</td>
<td>/mo</td>
</tr>
<tr>
<td>PSA</td>
<td>/mo</td>
</tr>
<tr>
<td>Others</td>
<td>/mo</td>
</tr>
</tbody>
</table>

Oral Chemotherapy: A. __________  B. __________

Reserve Agents

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[Signature]

James W. Forsythe MD, HMD

31
Standard 3 weeks
The Immune Protocol ™ The Lite LDIPT Protocol ™
(06/10-12/14)

• Monday – Immune Protocol ™ + LAPd IV
• Tuesday – Lite LDIPT ™ + L-Glutathione IV
• Wednesday - Super “C” – 50 grams + H2O2 IV
• Thursday – Lite LDIPT ™ + L-Glutathione IV
• Friday – Immune Protocol ™ + LAPd

DC to home on maintenance  CT / Targeted treatments for 3 mos-return visits after 3 mos

Monitor appropriate  X-Rays, MRIs, US’s, and CXR’s
## RGCC TESTING LAB – GENE PROBES

<table>
<thead>
<tr>
<th>TS</th>
<th>DNA</th>
<th>EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHFR</td>
<td>M-TRANS</td>
<td>TGFb</td>
</tr>
<tr>
<td>TUBULIN</td>
<td>O6AT</td>
<td>MMP9</td>
</tr>
<tr>
<td>TOPO</td>
<td>DNAdeam</td>
<td>NUC-REDUCT</td>
</tr>
<tr>
<td>SHMT</td>
<td>MPP</td>
<td>COX-2</td>
</tr>
<tr>
<td>DPD</td>
<td>LRP</td>
<td>S-lox</td>
</tr>
<tr>
<td>IP</td>
<td>GST</td>
<td>SS-r</td>
</tr>
<tr>
<td>p27</td>
<td>BEGF</td>
<td>C-erb2</td>
</tr>
<tr>
<td>p53</td>
<td>PDGF</td>
<td></td>
</tr>
</tbody>
</table>
## The Greek RGCC Supplement
Sample Recommendations

<table>
<thead>
<tr>
<th>Artemesia</th>
<th>PLA</th>
<th>Salvestrol</th>
<th>Ellagic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>H2O2</td>
<td>Thalid</td>
<td>Uncara tom</td>
<td>L-Meth</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>Quercetin</td>
<td>Carctrol</td>
<td>NAC</td>
</tr>
<tr>
<td>Vitamin B6</td>
<td>Cox-2</td>
<td>Noni juice</td>
<td>Vitamin B3</td>
</tr>
<tr>
<td>Mistletoe</td>
<td>Cytokines</td>
<td>Acetogen</td>
<td>L-carnitine</td>
</tr>
<tr>
<td>Ukrain</td>
<td>Carnivora</td>
<td>Cesium Cl</td>
<td>Vitamin E</td>
</tr>
<tr>
<td>Vitamin B17</td>
<td>COQ 10</td>
<td>Mitake</td>
<td>SOD</td>
</tr>
<tr>
<td>Coll Silver</td>
<td>Essiac tea</td>
<td>Curcumin</td>
<td>Selenium</td>
</tr>
<tr>
<td>DIM</td>
<td>Mod cit pec</td>
<td>Green tea</td>
<td>Aloe Vera</td>
</tr>
<tr>
<td>C-Statin</td>
<td>IP-6</td>
<td>Melatonin</td>
<td>Alpha IFN</td>
</tr>
</tbody>
</table>
### RGCC Chemosensitivity Testing Commonly Recorded Supplements

<table>
<thead>
<tr>
<th>Supplement</th>
<th>Supplement Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quercetin</td>
<td>PLA</td>
</tr>
<tr>
<td>Artemesia</td>
<td>Salvestrol</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>Ukrain</td>
</tr>
<tr>
<td>C-Statin</td>
<td>DIM</td>
</tr>
<tr>
<td>Vitamin D3</td>
<td>Paw-Paw</td>
</tr>
<tr>
<td>Mistletoe</td>
<td>Curcumin</td>
</tr>
</tbody>
</table>
Total Survivors on The Immune and Lite LDIPT Protocols + CST 750 Patients 54 Months Study

Survivors: 482/750
Percent Survivors = 64%
The Immune Protocol™
CST + The Lite LDIPT Protocol™

Response Rates at 54 months 750 patients with Stage IV Cancers

<table>
<thead>
<tr>
<th>Cancer Origin</th>
<th>Total #</th>
<th>% Survivors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td>15</td>
<td>60</td>
</tr>
<tr>
<td>Brain</td>
<td>14</td>
<td>64</td>
</tr>
<tr>
<td>Breast</td>
<td>140</td>
<td>72</td>
</tr>
<tr>
<td>Colorectal</td>
<td>57</td>
<td>61</td>
</tr>
<tr>
<td>Gastric/Eosoph</td>
<td>10</td>
<td>50</td>
</tr>
<tr>
<td>Head/Neck</td>
<td>26</td>
<td>57</td>
</tr>
<tr>
<td>Myeloma</td>
<td>17</td>
<td>76</td>
</tr>
<tr>
<td>NHL/CLL</td>
<td>17</td>
<td>76</td>
</tr>
</tbody>
</table>
The Immune Protocol ™
CST + The Lite LDIPT Protocol™
Response Rates at 54 months 750 patients with Stage IV Cancers

<table>
<thead>
<tr>
<th>Cancer Origin</th>
<th>Total #</th>
<th>% Survivors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovary</td>
<td>27</td>
<td>51</td>
</tr>
<tr>
<td>PAN/GB</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>Prostate</td>
<td>47</td>
<td>73</td>
</tr>
<tr>
<td>Renal Cell</td>
<td>11</td>
<td>54</td>
</tr>
<tr>
<td>Sarcomas</td>
<td>10</td>
<td>60</td>
</tr>
<tr>
<td>Thyroid</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>UT/CX</td>
<td>23</td>
<td>39</td>
</tr>
</tbody>
</table>
Overview

The Contribution of Cytotoxic Chemotherapy to 5-year Survival in Adult Malignancies

Graeme Morgan*, Rohyn Ward, Michael Bartlett
*Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW; †Department of Medical Oncology, St Vincent’s Hospital, Sydney, NSW; ‡Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Health Service, Sydney, NSW, Australia

ABSTRACT

Aims: The debate on the funding and availability of cytotoxic drugs raises questions about the contribution of curative or adjuvant cytotoxic chemotherapy to survival in adult cancer patients.

Materials and methods: We undertook a literature search for randomized clinical trials reporting a 5-year survival benefit attributable solely to cytotoxic chemotherapy in adult malignancies. The total number of newly diagnosed cancer patients for 22 major adult malignancies was determined from cancer registry data in Australia and from the Surveillance Epidemiology and End Results data in the USA for 1993. For each malignancy, the absolute number to benefit was the product of (a) the total number of patients with that malignancy, (b) the proportion of patients with that malignancy showing a benefit, and (c) the percentage increase in 5-year survival due solely to cytotoxic chemotherapy. The overall contribution was the sum total of the absolute numbers showing a 5-year survival benefit expressed as a percentage of the total number for the 22 malignancies.

Results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.

Conclusion: As the 5-year relative survival rate for cancer in Australia is over 60%, it is clear that cytotoxic chemotherapy alone makes a major contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required. Morgan, G. et al. (2004). Clinical Oncology 16, 549–560

© 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Key words: Chemotherapy, combined modality treatment, radiation, quality of life, mortality, survival
## Stage IV Cancer Case Histories

The Forsythe Immune Protocol ™
CST + The Forsythe Lite LDIPT Protocol ™

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>R/G</th>
<th>Cancer</th>
<th>Mets</th>
</tr>
</thead>
<tbody>
<tr>
<td>R.T.</td>
<td>57</td>
<td>WF</td>
<td>Left Breast</td>
<td>Chest Wall</td>
</tr>
<tr>
<td>I.D.</td>
<td>58</td>
<td>BF</td>
<td>Ovarian</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>C.C.</td>
<td>73</td>
<td>WF</td>
<td>Esophageal</td>
<td>Lung</td>
</tr>
<tr>
<td>E.U.</td>
<td>64</td>
<td>WF</td>
<td>Ovarian</td>
<td>Lung</td>
</tr>
<tr>
<td>E.D.</td>
<td>77</td>
<td>WM</td>
<td>ST Sarcoma</td>
<td>Testes</td>
</tr>
<tr>
<td>P.N.</td>
<td>48</td>
<td>WM</td>
<td>Appendix</td>
<td>Pseudomyxoma Peritoneii</td>
</tr>
<tr>
<td>J.S.</td>
<td>27</td>
<td>WF</td>
<td>Hodgkin</td>
<td>chest</td>
</tr>
</tbody>
</table>
### Stage IV Cancer Case Histories

**The Forsythe Immune Protocol™**

**CST + The Forsythe Lite LDIPT Protocol™**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>R/G</th>
<th>Cancer</th>
<th>Mets</th>
</tr>
</thead>
<tbody>
<tr>
<td>G.T.</td>
<td>69</td>
<td>WM</td>
<td>Prostate</td>
<td>L-S Spine</td>
</tr>
<tr>
<td>W.G.</td>
<td>77</td>
<td>WM</td>
<td>Prostate</td>
<td>Bones</td>
</tr>
<tr>
<td>R.W.</td>
<td>66</td>
<td>WF</td>
<td>Breast</td>
<td>Bones</td>
</tr>
<tr>
<td>A.A.</td>
<td>27</td>
<td>WF</td>
<td>NHL</td>
<td>Spinal</td>
</tr>
<tr>
<td>J.T.</td>
<td>28</td>
<td>WM</td>
<td>CRC</td>
<td>Peritoneal</td>
</tr>
<tr>
<td>M.N.</td>
<td>48</td>
<td>WF</td>
<td>Thyroid</td>
<td>Lungs</td>
</tr>
<tr>
<td>B.B.</td>
<td>46</td>
<td>WM</td>
<td>Rt Ft GBM</td>
<td>-</td>
</tr>
</tbody>
</table>
Stage IV Cancer Case Histories
The Forsythe Immune Protocol ™
CST + The Forsythe Lite LDIPT Protocol ™

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>R/G</th>
<th>Cancer</th>
<th>Mets</th>
</tr>
</thead>
<tbody>
<tr>
<td>K.P.</td>
<td>65</td>
<td>WF</td>
<td>Renal</td>
<td>Lung</td>
</tr>
<tr>
<td>C.S.</td>
<td>75</td>
<td>WM</td>
<td>Prostate</td>
<td>Bones</td>
</tr>
<tr>
<td>J.J.</td>
<td>52</td>
<td>WF</td>
<td>NHL</td>
<td>Lung</td>
</tr>
<tr>
<td>C.M.</td>
<td>54</td>
<td>WM</td>
<td>Myeloma</td>
<td>Bones</td>
</tr>
<tr>
<td>C.C.</td>
<td>69</td>
<td>WM</td>
<td>Prostate</td>
<td>Spine &amp; Pelvic</td>
</tr>
<tr>
<td>M.C.</td>
<td>73</td>
<td>WF</td>
<td>NSC Lung</td>
<td>Liver</td>
</tr>
</tbody>
</table>
Case # 1 R.T.

A 57 y.o. postmenopausal, white female with Stage IV left Breast CA with chest wall mets. DX 2008. Tumor ER/PR (+) and HER-2 (-). Tumor makers normal at time of dx. Mets when came to clinic in 2009 and started treatment in 2010 with The Immune Protocol ™ using LAPd following chemosensitivity genomic testing on CTC’s. Following the gene testing she was offered The Lite LDIPT Protocol ™, to be given over a three week period, twice weekly, with The Immune Protocol ™ on Monday, Wednesday and Friday. The Immune Protocol ™ consisted of LAPd, hydrogen peroxide, high dose Vit C, The Immune Protocol™ I.V., and the L-glut-I.V. The patient is seen at yearly intervals. She continues free of disease and with no evidence of residual disease in her chest wall or elsewhere. Her performance status is 100%.
Case # 2 I.D.

A 58 y.o. postmenopausal, black female dx with Stage IV adenocarcinoma of the ovaries with mets to her lungs and mediastinum in 2008. Her initial conventional tx was that of standard protocol chemo with carboplatin plus Taxol. First seen by me in 2010 and offered genomic testing. This was done and she was treated with The Immune Protocol ™ + LAPd using the two best drugs offered by the gene report. Drugs given twice weekly with The Lite LDIPT Protocol ™, and on Mondays, Wednesdays and Fridays of each week she was given the various immune therapies as listed above. CT scan of abdomen and chest showed no disease. Her cancer maker CA 125 is normal has been off all chemo and hormonal therapies for the past four years.
Case # 3 C.C.

74 y.o. widowed white female dx with Stage IV adenocarcinoma of the gastroesophageal junction in 2006. Refused chemo as she had mets to her lungs, given six months to one year prognosis. First seen by me in 2008 for second opinion offered genomic testing and IPT. Returned started tx in 2010 with The Immune Protocol™ consisting of three days per week of immune-stimulating therapy plus , LAPd and two days per week of The Lite LDIPT Protocol™. The patient has been in a prolonged, complete remission showing disappearance of all chest wall metastases and no new lesions in her mediastinum, liver, lungs or bones. Her tumor markers, CEA and CA 19-9 remain normal and she has a 90% performance status for four years.
Case # 4 E.D.

A 77-year-old, divorced, white male who was dx in 2009 as having liposarcoma with mets into the right testes, right inguinal canal, and the right groin. Started tx in 2010 with The Immune Protocol ™ three days per week, The Lite LDIPT Protocol ™ two days per week for a three-week period, and then he was discharged on oral chemo and followed at three-month intervals until this date. He continues to survive and has a 100% performance status. As no tumor markers are available for sarcomas, no lab confirmations of his complete remission are available other than the follow-up scans, pelvic x-rays and ultrasounds of this area.
Case # 5 P.N.

A 48-year-old, white, single male who was diagnosed with adenocarcinoma of the appendix complicated by massive ascites and a condition called "pseudomyxoma peritonei". The patient was first dx in 2008 with exploratory laparotomy. He refused all conventional therapies, including aggressive surgery, radiation and chemo. He came to see me in 2009, and after agreeing to CST started tx in 2010 given The Immune Protocol™ + LAPd three days per week, The Lite LDIPT Protocol™ two days per week for a three-week period, and then discharged on oral-effective chemo agents at a 50% dosage. The patient has required no paracentesis, as the ascites fluid is very thick, mucoid and gelatinous, and it is possible to drain through a standard paracentesis procedure. The patient is well-controlled, has some ascites, but functional and maintains a part-time employment in a stable remission and has not used any ambulatory-assistive devices.
Case # 6 M.N.

A 49-year-old, white, married female, college professor, who was diagnosed with Stage IV papillary thyroid carcinoma with pulmonary metastases in 2008. She was first seen by me in 2010 and received CST, following which she was treated with The Immune Protocol™ + LAPd three days per week and The Lite LDipt Protocol™ two days per week. This resulted in a complete remission with disappearance of all lung metastases and the development of a 100% performance status. The patient has been off all chemotherapy treatments for the past three years.
Case # 7 B.B.

A 46-year-old, white, married male who was diagnosed with a right frontal lobe anaplastic astrocytoma in 2009. The patient had a subtotal right frontal craniectomy procedure, with tumor left behind because of its involvement in the right motor strip parietal area. The patient first saw me in 2010 and was treated with the Immune Protocol™ and The Lite LDIPT Protocol™ + LAPd followed by oral CCNU. He has been in a complete remission with follow-up MRI studies showing no residual tumor in the right frontal area nor any other new lesions elsewhere in the brain. The patient has had maintenance therapy with hemp oil and has otherwise been stable. The patient is alive with normal cognitive functioning at over 5 years.
Case # 8 T.M.

A 44-year-old, white, married male with Stage IV adenocarcinoma of the pancreas with liver mets, dx via needle biopsy for liver mets in 2010. This patient was initially seen by me shortly after his dx and underwent CST, which was followed by tx with The Lite LDIPT Protocol™ given twice weekly for three weeks, with the other three days per week being occupied by treatment with The Immune Protocol™ plus LAPd. Following three weeks of I.V. therapy the patient was sent home on oral Tarceva, to be taken once daily. The patient has been in a stable remission for the past four years and he has not required other systemic, low-dose chemo.
Case # 9 C.M.

A 54-year-old, white, married male, doctor of chiropractic's, who was dx with multiple myeloma in 2005. He received conventional therapies for the next several years. He first saw me in 2010 with Stage IV disease, with extensive bony mets. He underwent CST followed by treatment with The Immune Protocol™ and LAPd. The Lite LDIPT Protocol™ was given two days per week with The Immune Protocol™ and other therapies given on Mondays, Wednesdays and Fridays for a three-week period. He was discharged on oral medications, according to genetic sensitivity testing. He has been in a prolonged durable remission for the past four years and has, in fact, written a book about his excellent progress.
Case # 10 K.P.

A 65-year-old, white, married female with renal cell carcinoma with mets to her lungs, and diagnosed with Stage IV disease at the time of diagnosis in 2007. The patient first saw me in 2010 and underwent chemosensitivity genomic testing. She was treated with The Immune Protocol™ plus LAPd three days per week and The Lite LDIPT Protocol™ two days per week. She was then discharged on oral medications and has been followed by myself and other physicians since that time. She currently remains in excellent remission for four years.
Advanced Stage Breast Cancer Survival Rate
Patients Diagnosed Between 2000-2005
Cancer Treatment Centers of America

<table>
<thead>
<tr>
<th>Years (after initial diagnosis)</th>
<th>CTCA</th>
<th>SEER</th>
<th>Patient Survival Rate</th>
<th>Points Higher</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>71%</td>
<td>93%</td>
<td></td>
<td>22% Points Higher</td>
</tr>
<tr>
<td>1</td>
<td>60%</td>
<td>88%</td>
<td></td>
<td>28% Points Higher</td>
</tr>
<tr>
<td>1.5</td>
<td>51%</td>
<td>76%</td>
<td></td>
<td>25% Points Higher</td>
</tr>
<tr>
<td>2</td>
<td>44%</td>
<td>63%</td>
<td></td>
<td>19% Points Higher</td>
</tr>
<tr>
<td>2.5</td>
<td>37%</td>
<td>56%</td>
<td></td>
<td>19% Points Higher</td>
</tr>
<tr>
<td>3</td>
<td>32%</td>
<td>46%</td>
<td></td>
<td>14% Points Higher</td>
</tr>
<tr>
<td>3.5</td>
<td>29%</td>
<td>42%</td>
<td></td>
<td>13% Points Higher</td>
</tr>
</tbody>
</table>

*www.cancercenter.com/breast-cancer/survival-outcome.cfm*
Immune Protocol™ / Lite LDIPT Protocol™ + CST Comparing Stage IV Breast Cancers

Survival Rate at 2 years

- NCI: 44%
- CTCA: 63%
- CWC: 85%
Conclusions: Conventional Chemotherapy Results

<table>
<thead>
<tr>
<th>* Five year Overall Survival Rate (OS) Stage IV Cancers</th>
<th>Adjuvant Cytotoxic Chemotherapy for 22 major adult malignancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>2.1%</td>
</tr>
<tr>
<td>Australia</td>
<td>2.3%</td>
</tr>
</tbody>
</table>

The Immune Protocol ™/ CST + Lite LDIPT Protocol ™ Summary
750 Patients over 54 months

- Integrative Oncology attempts to treat the whole patient-not just an organ i.e. prostate, lung, etc…
- CWC patients undergo a thorough hx and physical exam and complete review of pathological, radiological and lab data similar to conventional oncology.
- More than the above CWC studies patients’ emotional health, underlying toxicities, toxic heavy metals, allergies, chemicals, dental health and infections.
The Immune Protocol™/ CST + Lite LDIPT Protocol™ Summary
750 Patients over 54 months

- The most important new addition to The Immune Protocol™ program is the addition of chemo-sensitivity testing - different families of chemotherapy agents along with 50 separate supplements performed on whole blood genetic decoding.
- The chemo-sensitivity labs internationally are: Germany – Biofocus; Greece-Research Genetic Cancer Centre.
- The 54 month results on 750 patients shows a survivorship of 64% – aiming for results for 5 years with 500 patients counted.
- The Immune Protocol™ / Lite LDIPT Protocol™ program offers patients a full spectrum menu which is based on their own choices guided by chemo-sensitivity and supplement sensitivity testing.
This is true provided that this improvement is not gained at the expense of toxic chemotherapy or radiation therapy leaving the patient with many of the following adverse side effects:

- Chemo Brain Syndrome
- Painful Neuropathies
- Cardiomyopathies
- Renal Failure / Platinum toxicities / Hepatic Failure
- Severe Pancytopenias
- Pulmonary Fibrosis
- Devastating Fatigue, Anorexia and Wasting Syndromes
- Osteoarthritis, myalgias, osteoporosis
- Severe dermatoses
- Death

This study shows that the “cure or kill” approach to advanced cancer treatment is not the only answer.
New Horizons in Integrative Medical Oncology

- HEMP Oil
- Ganoderma
- Scorpion/Spider Venoms/Bee Stings
- Far-Infrared Saunas and Bio-mats
- Metformin
- Melatonin
- BX Vaccine
- NALTREXONE
- SOT Vaccine
Cancer Patients’ Bill of Rights

2. Alternate Path          7. Important Knowledge
3. Stay Alert              8. Be Wary of Media
5. Eat Organic             10. Limit Pharmaceuticals
Freedom of Healing Is Your Right

“The Constitution of this Republic should make provisions for healing freedom as well as religious freedom. To restrict the art of healing to one class of men and deny equal privileges to others will constitute the bastille of medical science. Such restrictions are fragments of monarchy and have no place in a republic.”

~Benjamin Rush, MD~
Dr. Forsythe’s Books

- Suzanne Somers’ number one best sellers: KNOCKOUT, Interviews with Doctors who are Curing Cancer (single chapter) & BREAKTHROUGH, Eight Steps to Wellness
- Alternative Medicine Definitive Guide to Cancer (single chapter)
- Dr. Forsythe’s Natural Health Guide For Common Diseases and Symptoms from A-Z
- Natural Pain Killers
- Take Control of Your Cancer-Kindle 2nd edition
- The Forsythe Anti-Cancer Diet
- The Healing Power of Sleep
- About Death from a Cancer Doctor’s Perspective
- Sleep and Grow Young
- Emergency Radiation Medical handbook, The Essential mandatory Guide for Citizens and Responders to Nuclear Events
- Complete Pain-Forget Everything You Thought You Knew About Pain
- Understanding and Surviving Obama Care
- Anti-Aging Cures
- Your Secret to the Fountain of Youth
- Dr. Forsythe’s Whey Protein Formula
Dr. Forsythe’s Best Sellers

The Forsythe Anti-Cancer Diet
James W. Forsythe M.D., H.M.D.

ANTI-AGING CURES
Your Key to the REAL Fountain of Youth
Life Changing Secrets To Reverse The Effects of Aging

Dr. James Forsythe
As Seen On TV
Bestselling Author

eforsythe@sbcglobal.net  www.DrForsythe.com
1.877.789.0707  1.775.827.0707